Share on StockTwits

NxStage Medical (NASDAQ:NXTM) SVP Winifred L. Swan sold 2,500 shares of NxStage Medical stock on the open market in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $13.60, for a total value of $34,000.00. Following the sale, the senior vice president now directly owns 20,188 shares of the company’s stock, valued at approximately $274,557. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

NxStage Medical (NASDAQ:NXTM) traded down 0.82% on Wednesday, hitting $13.29. 32,427 shares of the company’s stock traded hands. NxStage Medical has a 1-year low of $8.77 and a 1-year high of $15.65. The stock has a 50-day moving average of $13.58 and a 200-day moving average of $13.30. The company’s market cap is $821.7 million.

NxStage Medical (NASDAQ:NXTM) last announced its earnings results on Thursday, August 7th. The company reported ($0.12) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.11) by $0.01. The company had revenue of $74.10 million for the quarter, compared to the consensus estimate of $70.52 million. During the same quarter last year, the company posted ($0.06) earnings per share. NxStage Medical’s revenue was up 13.3% compared to the same quarter last year. On average, analysts predict that NxStage Medical will post $-0.45 earnings per share for the current fiscal year.

A number of research firms have recently commented on NXTM. Analysts at Piper Jaffray raised their price target on shares of NxStage Medical from $16.00 to $18.00 in a research note on Friday, August 8th. Analysts at Canaccord Genuity raised their price target on shares of NxStage Medical from $19.00 to $20.00 in a research note on Friday, August 8th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating and one has issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $18.25.

NxStage Medical, Inc (NASDAQ:NXTM) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.